BRAF mutated anaplastic thyroid carcinoma: clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network.
A. Jannina (Dr), C. De La Fouchardiere*b (Dr), A. Janninc (Dr), F. Giudicid (Dr), J. Wassermanne (Dr), CN. Chougnetf (Dr), D. Druig (Dr), Y. Godberth (Dr), F. Illouzi (Dr), S. Bardetj (Dr), I. Dygai-Cochetk (Dr), N. Roudautl (Dr), M. Batisse-Lignierm (Dr), L. Groussinn (Pr), M. Kleino (Pr), S. Zerdoudp (Dr), L. Lamartinaq (Dr), E. Baudinq (Dr), F. Borson-Chazotr (Pr), C. Do Caoc (Dr), I. Borgetd (Dr), J. Hadouxq (Dr)
a CHU de Lille, Lille, FRANCE ; b Centre Léon-Bérard, département de cancérologie médicale, Lyon, FRANCE ; c CHU de Lille, hôpital Claude-Huriez, service d'endocrinologie diabétologie métabolisme nutrition, Lille, FRANCE ; d service de biostatistique et d'épidémiologie, Villejuif, France; Université Paris-Saclay, Équipe labellisée Ligue contre le cancer, GRADES, Oncostat U1018, Inserm, Villejuif, FRANCE ; e Hôpital Pitié-Salpêtrière, service d'oncologie médicale, Paris, FRANCE ; f Hôpital Saint-Louis, service d'oncologie endocrinienne, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, FRANCE ; g CHU de Nantes-Hopital Laennec Saint-Herblain, Institut du Thorax, Service d'endocrinologie,, Nantes, FRANCE ; h Institut Bergonié Bordeaux, département de cancérolgie endocrinienne et médecine nucleaire, Bordeaux, FRANCE ; i CHU Angers, Centre de Référence Maladies Rares de la Thyroïde et des Récepteurs Hormonaux, Service Endocrinologie-Diabétologie-Nutrition,, Angers, FRANCE ; j Centre François-Baclesse, service de médecine nucléaire et UCP thyroïde, Caen, FRANCE ; k Centre Georges François Leclerc, Service de médecine nucléaire, Dijon, FRANCE ; l CHU La Cavale Blanche, Service d'Endocrinologie, Paris, FRANCE ; m Centre Jean Perrin, service de médecine nucléaire, Clermont-Ferrand, FRANCE ; n Hôpital Cochin, AP-HP, service d'endocrinologie, Paris, FRANCE ; o Centre Hospitalier Régional Universitaire de Nancy, Hôpitaux de Brabois, Service d'endocrinologie, Nancy, FRANCE ; p Institut universitaire du cancer Toulouse - Oncopole, département de médecine nucléaire, Toulouse, FRANCE ; q Institut Gustave-Roussy et université Paris-Saclay, Service de médecine nucléaire et d'oncologie endocrinienne., Villejuif, FRANCE ; r Hôpital Louis-radel, Hospices Civils de Lyon, Fédération d'endocrinologie, Lyon, FRANCE
* christelle.delafouchardiere@lyon.unicancer.fr
Objective: The aim of the study was to analyze clinical and biological characteristics and outcome of ATC patients with BRAF-mutations.
Methods: ATC patients diagnosed between 2010 and 2020 were identified in our ENDOCAN-TUTHYREF national database. Overall survival (OS) and progression free survival after 1st line treatment (1L-PFS) were determined by the Kaplan-Meier method.
Results: Among the whole cohort of 360 ATCs, 212 had a molecular analysis and 53 pts (25%) had a BRAF mutation, including 48 with a BRAF-V600E mutation. The median age was 72 years (range:50-96). One patient (2%) had stage IVa, 14 (28%) had stage IVb and 36 (71%) had stage IVc the stage distribution was not different compared with BRAF wild-type (WT) pts.
Median OS in the BRAF-mutated cohort was 6.88 months (95% CI: 3.60-10.45) versus 11.27 (9.09-14.05) in WT patients (p=0.08), regardless the disease stage.
Among the 53 BRAF-mutated patients, 21 (40%) received BRAF inhibitors: 17 Dabrafenib+Trametinb (8 as 1st line and 9 post-chemotherapy (CT) with a median OS of 14.21 months (4.66-NA) and a median 1L-PFS of 6.38 months (1.79-NA), 4 were treated with Vemurafenib (1 as 1L and 3 post-CT, median OS: 14.91 months (6.88-NA),18 received only CT (OS: 4.05 months (0.83-8.83) and 1L-PFS: 2.15 months (0.66 -4.56)) and 14 without CT (OS: 1.31 months (0.56-NA).
Conclusions: These results confirm the clinical benefit of BRAF inhibitors in BRAF-mutated ATC in a real-life population. BRAF inhibitors improved OS and represents a meaningful treatment option for this aggressive cancer.
L’auteur n’a pas transmis de déclaration de conflit d’intérêt.